Sugi Predict

Sugi Predict / Targets / HAVCR2

HAVCR2

Hepatitis A virus cellular receptor 2 · Q8TDQ0 · HAVCR2 on Sugi Atlas →

4,370 patent compounds predicted against HAVCR2, 2,472 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL404463 SCHEMBL404463 0.71 20/20
SCHEMBL404891 SCHEMBL404891 0.70 20/20
SCHEMBL405680 SCHEMBL405680 0.64 20/20
SCHEMBL462807 SCHEMBL462807 0.60 20/20
SCHEMBL405064 SCHEMBL405064 0.67 19/20
SCHEMBL405538 SCHEMBL405538 0.63 19/20
SCHEMBL404677 SCHEMBL404677 0.60 19/20
SCHEMBL405861 SCHEMBL405861 0.60 19/20
SCHEMBL462917 SCHEMBL462917 0.55 19/20
SCHEMBL463665 SCHEMBL463665 0.55 19/20
SCHEMBL406263 SCHEMBL406263 0.55 19/20
SCHEMBL405740 SCHEMBL405740 0.71 18/20
SCHEMBL404764 SCHEMBL404764 1.00 17/20
SCHEMBL405565 SCHEMBL405565 1.00 17/20
SCHEMBL404765 SCHEMBL404765 0.75 17/20
SCHEMBL463399 SCHEMBL463399 0.67 17/20
SCHEMBL405859 SCHEMBL405859 0.51 17/20
SCHEMBL404656 SCHEMBL404656 0.75 16/20
SCHEMBL462802 SCHEMBL462802 0.67 15/20
SCHEMBL6804740 SCHEMBL6804740 0.64 15/20

Clinical trials — most relevant to HAVCR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Improved Prevention of Perinatal Hepatitis B Transmission PHASE4UNKNOWN
HBsAg Related Response Guided Therapy PHASE4UNKNOWN
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 PHASE1/PHASE2UNKNOWN
Durvalumab and Tremelimumab in Resectable HCC PHASE2RECRUITING
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma PHASE1/PHASE2COMPLETED
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery PHASE1/PHASE2UNKNOWN
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab PHASE2COMPLETED
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) PHASE1/PHASE2NOT_YET_RECRUITING
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma PHASE1/PHASE2RECRUITING
A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) PHASE2ACTIVE_NOT_RECRUITING
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL PHASE1/PHASE2RECRUITING
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma PHASE2RECRUITING
Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation PHASE2NOT_YET_RECRUITING
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis PHASE1/PHASE2WITHDRAWN
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2 PHASE1COMPLETED
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 PHASE1WITHDRAWN
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies PHASE1COMPLETED
A Phase I Dose Finding Study of MB-CART2219.1 PHASE1RECRUITING
Neoadjuvant Atezolizumab in Cutaneous Melanoma PHASE1ACTIVE_NOT_RECRUITING
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Immunity With Acute Hepatits A nanNOT_YET_RECRUITING
Collection of Tissue Samples for Cancer Research nanRECRUITING
T Regulatory Cells in Hepatitis c Infected Patients nanCOMPLETED
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer nanCOMPLETED
Biological Therapy in Treating Patients With Advanced Cancer nanCOMPLETED
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a HAVCR2 binder may also engage these)

ProteinNameSimilarity
Q8VIM0 — 1.000 Q8VIM0 →
Q8R183 — 0.998 Q8R183 →
P0C0K5 — 0.998 P0C0K5 →
Q5QNS5 — 0.994 Q5QNS5 →
Q5FVR0 — 0.993 Q5FVR0 →
Q9Z0K5 — 0.993 Q9Z0K5 →
Q96D42 — 0.992 Q96D42 →
Q8R4V1 — 0.992 Q8R4V1 →
Q7TSA3 — 0.992 Q7TSA3 →
Q96PD2 — 0.991 Q96PD2 →
P0C6B7 — 0.990 P0C6B7 →
O54947 — 0.990 O54947 →
P16872 — 0.990 P16872 →
Q5M871 — 0.990 Q5M871 →
P86176 — 0.989 P86176 →
Q9D9J7 — 0.989 Q9D9J7 →
O95976 — 0.989 O95976 →
Q96H15 — 0.988 Q96H15 →
A6QQC6 — 0.988 A6QQC6 →
P01590 — 0.988 P01590 →
Q6U7R4 — 0.988 Q6U7R4 →
Q01151 — 0.988 Q01151 →
Q9GKE2 — 0.987 Q9GKE2 →
P16743 — 0.987 P16743 →
Q8K4B4 — 0.987 Q8K4B4 →
Q6AXU5 — 0.987 Q6AXU5 →
T1NXB5 — 0.987 T1NXB5 →
Q4W815 — 0.987 Q4W815 →
Q2YHT7 — 0.987 Q2YHT7 →
Q80UL9 — 0.986 Q80UL9 →